Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunovion Pharmaceuticals' Latuda (lurasidone HCl) tablets have received approval from the US Food and Drug Administration (FDA) for the treatment of adults with schizophrenia.
Subscribe to our email newsletter
Sunovion Pharma said that Latuda is included in the atypical antipsychotic class of drugs.
FDA Center for Drug Evaluation and Research Division of Psychiatry Products director Thomas Laughren said that some patients do not respond well to certain types of drug therapy, so it is important to have multiple treatment options available.
Four six-week controlled studies of adults with schizophrenia demonstrated the effectiveness and safety of Latuda.
In the trials, patients treated with Latuda had fewer symptoms of schizophrenia than those taking an inactive pill (placebo).